RU2014111179A - КОНЪЮГАТЫ ИНТЕРФЕРОНА λ1 И ПОЛИЭТИЛЕНГЛИКОЛЯ - Google Patents
КОНЪЮГАТЫ ИНТЕРФЕРОНА λ1 И ПОЛИЭТИЛЕНГЛИКОЛЯ Download PDFInfo
- Publication number
- RU2014111179A RU2014111179A RU2014111179/10A RU2014111179A RU2014111179A RU 2014111179 A RU2014111179 A RU 2014111179A RU 2014111179/10 A RU2014111179/10 A RU 2014111179/10A RU 2014111179 A RU2014111179 A RU 2014111179A RU 2014111179 A RU2014111179 A RU 2014111179A
- Authority
- RU
- Russia
- Prior art keywords
- interferon
- conjugate
- polyethylene glycol
- conjugate according
- alkyl
- Prior art date
Links
- 102100020990 Interferon lambda-1 Human genes 0.000 title claims abstract 18
- 101710099623 Interferon lambda-1 Proteins 0.000 title claims abstract 18
- 239000002202 Polyethylene glycol Substances 0.000 title claims abstract 10
- 229920001223 polyethylene glycol Polymers 0.000 title claims abstract 10
- 125000000217 alkyl group Chemical group 0.000 claims abstract 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 5
- -1 4-nitrophenoxycarbonyl Chemical group 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims abstract 4
- 208000005176 Hepatitis C Diseases 0.000 claims abstract 3
- 230000021615 conjugation Effects 0.000 claims abstract 3
- 208000002672 hepatitis B Diseases 0.000 claims abstract 3
- 230000014759 maintenance of location Effects 0.000 claims abstract 3
- 210000002966 serum Anatomy 0.000 claims abstract 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims abstract 2
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- 125000003827 glycol group Chemical group 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 229930182817 methionine Natural products 0.000 claims abstract 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims 12
- 208000036142 Viral infection Diseases 0.000 claims 4
- 230000009385 viral infection Effects 0.000 claims 4
- 229960004556 tenofovir Drugs 0.000 claims 3
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229960000329 ribavirin Drugs 0.000 claims 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 239000002777 nucleoside Substances 0.000 claims 1
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 1
- NHKZSTHOYNWEEZ-AFCXAGJDSA-N taribavirin Chemical compound N1=C(C(=N)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NHKZSTHOYNWEEZ-AFCXAGJDSA-N 0.000 claims 1
- 229950006081 taribavirin Drugs 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 abstract 2
- 108010050904 Interferons Proteins 0.000 abstract 2
- 229940079322 interferon Drugs 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| VNVN1-2011-02222 | 2011-08-25 | ||
| VN201102222 | 2011-08-25 | ||
| PCT/US2012/027317 WO2013028233A1 (en) | 2011-08-25 | 2012-03-01 | Peg-interferon lambda 1 conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014111179A true RU2014111179A (ru) | 2015-09-27 |
Family
ID=47746747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014111179/10A RU2014111179A (ru) | 2011-08-25 | 2012-03-01 | КОНЪЮГАТЫ ИНТЕРФЕРОНА λ1 И ПОЛИЭТИЛЕНГЛИКОЛЯ |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP2748328A4 (https=) |
| JP (1) | JP2014525939A (https=) |
| CN (1) | CN103228792A (https=) |
| AU (1) | AU2012299423A1 (https=) |
| BR (1) | BR112014004302A2 (https=) |
| CA (1) | CA2846092A1 (https=) |
| RU (1) | RU2014111179A (https=) |
| WO (1) | WO2013028233A1 (https=) |
| ZA (1) | ZA201401159B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7674628B2 (ja) | 2016-02-19 | 2025-05-12 | イーアイティー・ファーマ・インコーポレイテッド | インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置 |
| ES3015227T3 (en) | 2017-03-16 | 2025-04-30 | Evangelos Andreakos | Use of lambda interferons in the treatment of an obesity-related disorder, atherosclerosis or a coagulation disorder |
| RU2678332C1 (ru) * | 2017-09-08 | 2019-01-28 | Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") | Пегилированный интерферон лямбда, обладающий высокой биодоступностью при пероральном применении, и способ его получения |
| CN112245570A (zh) | 2019-07-22 | 2021-01-22 | 厦门特宝生物工程股份有限公司 | 一种基于干扰素的疾病治疗方法 |
| JP2024504341A (ja) | 2021-01-21 | 2024-01-31 | シャーメン アモイトップ バイオテック カンパニー， リミテッド | 癌を治療するためのインターフェロンベースの方法及び組合せ医薬 |
| EP4282426A4 (en) | 2021-01-21 | 2024-11-27 | Xiamen Amoytop Biotech Co., Ltd. | Method and pharmaceutical combination for preventing cancer recurrence |
| WO2024121424A1 (en) | 2022-12-09 | 2024-06-13 | Daniel Zagury | Composite aids vaccine generating anti-hiv specific neutralizing antibodies and/or anti-hiv cytotoxic t cells |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| CN1176137C (zh) * | 2002-01-15 | 2004-11-17 | 泛亚生物技术有限公司 | 多臂树杈型功能化聚乙二醇制备方法及它在药物中的应用 |
| CN1927388B (zh) * | 2004-09-10 | 2011-02-02 | 北京金迪克生物技术研究所 | 含有人干扰素的药物组合物 |
| WO2006133089A2 (en) * | 2005-06-03 | 2006-12-14 | Ambrx, Inc. | Improved human interferon molecules and their uses |
| WO2007041713A1 (en) * | 2005-10-04 | 2007-04-12 | Zymogenetics, Inc. | Production and purification of il-29 |
| CN101002942B (zh) * | 2007-01-08 | 2010-07-21 | 湖南大学 | 一种peg化脂质体纳米颗粒 |
| JP2011522834A (ja) * | 2008-06-05 | 2011-08-04 | ザイモジェネティクス リミテッド ライアビリティ カンパニー | Ｃ型肝炎の治療のためのペグ化ｉｉｉ型インターフェロンの使用 |
-
2012
- 2012-03-01 BR BR112014004302A patent/BR112014004302A2/pt not_active IP Right Cessation
- 2012-03-01 RU RU2014111179/10A patent/RU2014111179A/ru not_active Application Discontinuation
- 2012-03-01 JP JP2014527142A patent/JP2014525939A/ja not_active Withdrawn
- 2012-03-01 CA CA2846092A patent/CA2846092A1/en not_active Abandoned
- 2012-03-01 EP EP12825651.8A patent/EP2748328A4/en not_active Withdrawn
- 2012-03-01 CN CN2012800033678A patent/CN103228792A/zh active Pending
- 2012-03-01 AU AU2012299423A patent/AU2012299423A1/en not_active Abandoned
- 2012-03-01 WO PCT/US2012/027317 patent/WO2013028233A1/en not_active Ceased
-
2014
- 2014-02-14 ZA ZA2014/01159A patent/ZA201401159B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012299423A1 (en) | 2014-03-06 |
| ZA201401159B (en) | 2015-04-29 |
| JP2014525939A (ja) | 2014-10-02 |
| CN103228792A (zh) | 2013-07-31 |
| EP2748328A1 (en) | 2014-07-02 |
| BR112014004302A2 (pt) | 2017-06-20 |
| WO2013028233A1 (en) | 2013-02-28 |
| EP2748328A4 (en) | 2015-03-04 |
| CA2846092A1 (en) | 2013-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014111179A (ru) | КОНЪЮГАТЫ ИНТЕРФЕРОНА λ1 И ПОЛИЭТИЛЕНГЛИКОЛЯ | |
| US10532086B2 (en) | Methods and compositions for modulating the immune system with arginase I | |
| RU2008126305A (ru) | Новый пептид | |
| US8454947B1 (en) | PEG-interferon lambda 1 conjugates | |
| KR102599942B1 (ko) | Hbv 및 hdv 감염의 조합 치료법 | |
| JP2011522834A5 (https=) | ||
| JP2010505831A5 (https=) | ||
| JP2014525939A5 (https=) | ||
| RU2010126598A (ru) | Применение человеческого антитела, способного нейтрализовать вирус гепатита в, для профилактики или лечения инфекции вирусом гепатита в | |
| US20150202218A1 (en) | Broad Spectrum Inhibitors of the Post Proline Cleaving Enzymes for Treatment of Hepatitis C Virus Infections | |
| RU2006101166A (ru) | Рекомбинантные антитела и композиции и способы их получения и использования | |
| EP2030628A1 (en) | A peptide for preventing or treating liver damage and its derivant and the use | |
| US20090035273A1 (en) | Combination treatment method with interferon-tau | |
| MX2008014358A (es) | Conjugado de polietilenglicol-interferon alfa. | |
| TW201010692A (en) | Pharmaceutical composition for treatment or prevention of hbv infection | |
| WO2016085279A2 (ko) | 세포 투과 펩타이드-면역조절제 접합체 및 이를 포함하는 면역질환 치료용 조성물 | |
| RU2597795C2 (ru) | Ингибитор скопления жидкости в полостях организма | |
| KR20250117319A (ko) | 미토콘드리아 기능 개선 펩타이드의 항암 용도 | |
| RU2008125167A (ru) | Терапевтическое средство для ускоренного заживления кожи, содержащее в качестве активного ингредиента дезацил-грелин и его производные | |
| KR20240159721A (ko) | 지방산-펩타이드 접합체 | |
| CN106132983A (zh) | 新型IFN‑β蛋白类似物 | |
| CN1264308A (zh) | 用于治疗免疫缺陷疾病的药物组合物 | |
| HK1262528A1 (en) | Diazabicyclo compounds for use in the treatment and/or prevention of diseases or conditions associated with hepatitis viruses | |
| HK1262528B (en) | Diazabicyclo compounds for use in the treatment and/or prevention of diseases or conditions associated with hepatitis viruses | |
| WO2001080877A1 (en) | Preventives for reinfection after liver transplantation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160914 |